Identification

Name
Amcinonide
Accession Number
DB00288  (APRD00788)
Type
Small Molecule
Groups
Approved
Description

Amcinonide is a corticosteroid. [Wikipedia]

Structure
Thumb
Synonyms
  • Amcinonida
  • Amcinonidum
  • Triamcinolonacetatcyclopentanonid
External IDs
CL 34699 / CL-34699
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CyclocortOintment0.1 %TopicalGlaxosmithkline Inc1997-01-20Not applicableCanada
CyclocortCream0.1 %TopicalGlaxosmithkline Inc1996-09-12Not applicableCanada
CyclocortLotion0.1 %TopicalGlaxosmithkline Inc1996-09-12Not applicableCanada
Cyclocort Crm 0.1%Cream.1 %TopicalLederle Cyanamid Canada Inc.1978-12-311997-01-29Canada
Cyclocort Lot 0.1%Lotion.1 %TopicalLederle Cyanamid Canada Inc.1983-12-311997-01-29Canada
Cyclocort Ont 0.1%Ointment.1 %TopicalLederle Cyanamid Canada Inc.1983-12-311997-01-29Canada
Ratio-amcinonideOintment0.1 %TopicalTeva2004-05-05Not applicableCanada
Ratio-amcinonideLotion0.1 %TopicalTeva2004-05-06Not applicableCanada
Ratio-amcinonideCream0.1 %TopicalTeva2003-09-18Not applicableCanada
Taro-amcinonideOintment0.1 %TopicalTaro Pharmaceuticals, Inc.Not applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AmcinonideCream1 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.2002-05-31Not applicableUs
AmcinonideOintment1 mg/gTopicalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.2014-04-03Not applicableUs
AmcinonideOintment1 mg/gTopicalTaro Pharmaceuticals U.S.A., Inc.2003-03-19Not applicableUs
AmcinonideLotion1 mg/gTopicalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.2002-11-06Not applicableUs
AmcinonideCream1 mg/gTopicalE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.2003-05-15Not applicableUs
International/Other Brands
Mycoderm / Penticort / Visderm
Categories
UNII
423W026MA9
CAS number
51022-69-6
Weight
Average: 502.5717
Monoisotopic: 502.236681679
Chemical Formula
C28H35FO7
InChI Key
ILKJAFIWWBXGDU-MOGDOJJUSA-N
InChI
InChI=1S/C28H35FO7/c1-16(30)34-15-22(33)28-23(35-26(36-28)9-4-5-10-26)13-20-19-7-6-17-12-18(31)8-11-24(17,2)27(19,29)21(32)14-25(20,28)3/h8,11-12,19-21,23,32H,4-7,9-10,13-15H2,1-3H3/t19-,20-,21-,23+,24-,25-,27-,28+/m0/s1
IUPAC Name
2-[(1'S,2'S,4'R,8'S,9'S,11'S,12'R,13'S)-12'-fluoro-11'-hydroxy-9',13'-dimethyl-16'-oxo-5',7'-dioxaspiro[cyclopentane-1,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-14',17'-dien-8'-yl]-2-oxoethyl acetate
SMILES
[H][[email protected]@]12C[[email protected]@]3([H])[[email protected]]4([H])CCC5=CC(=O)C=C[[email protected]]5(C)[[email protected]@]4(F)[[email protected]@H](O)C[[email protected]]3(C)[[email protected]@]1(OC1(CCCC1)O2)C(=O)COC(C)=O

Pharmacology

Indication

For the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Structured Indications
Pharmacodynamics

Amcinonide is a topical corticosteroid. The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. Amcinonide reduces or inhibits the actions of chemicals in the body that cause inflammation, redness, and swelling. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. When in an ointment form, amcinonide also helps the skin maintain moisture.

Mechanism of action

The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Amcinonide has affinity for the glucocorticoid receptor. It has weak affinity for the progesterone receptor, and virtually no affinity for the mineralocorticoid, estrogen, or androgen receptors.

TargetActionsOrganism
AGlucocorticoid receptor
agonist
Human
UAnnexin A1
agonist
Human
Absorption

Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys.

Route of elimination

Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

Half life
Not Available
Clearance
Not Available
Toxicity

Results from acute toxicity studies do not indicate that any risk of acute intoxication is to be expected following a single dermal application of an overdose (application over a large area under conditions favorable to absorption) or inadvertent oral ingestion.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Amcinonide is combined with 1,10-Phenanthroline.Experimental
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Amcinonide.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Amcinonide.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Amcinonide.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Amcinonide.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Amcinonide.Approved, Withdrawn
AldesleukinAmcinonide may decrease the antineoplastic activities of Aldesleukin.Approved
AlgeldrateThe bioavailability of Amcinonide can be decreased when combined with Algeldrate.Approved, Experimental
AlmagateThe bioavailability of Amcinonide can be decreased when combined with Almagate.Experimental
AlmasilateThe bioavailability of Amcinonide can be decreased when combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Amcinonide.Experimental
AloglutamolThe bioavailability of Amcinonide can be decreased when combined with Aloglutamol.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Amcinonide.Experimental
AluminiumThe bioavailability of Amcinonide can be decreased when combined with Aluminium.Approved
Aluminium acetoacetateThe bioavailability of Amcinonide can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Amcinonide can be decreased when combined with Aluminium glycinate.Experimental
Aluminum hydroxideThe bioavailability of Amcinonide can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Amcinonide is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Amcinonide.Approved
AmiodaroneThe serum concentration of Amcinonide can be increased when it is combined with Amiodarone.Approved, Investigational
Amphotericin BAmcinonide may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Amcinonide.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Amcinonide.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Amcinonide.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Amcinonide.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Amcinonide.Approved, Investigational
AprepitantThe serum concentration of Amcinonide can be increased when it is combined with Aprepitant.Approved, Investigational
AtazanavirThe serum concentration of Amcinonide can be increased when it is combined with Atazanavir.Approved, Investigational
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Amcinonide.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Amcinonide.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Amcinonide.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Amcinonide.Approved, Investigational
BCG vaccineThe risk or severity of adverse effects can be increased when Amcinonide is combined with BCG vaccine.Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Amcinonide.Experimental
BendroflumethiazideAmcinonide may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Amcinonide.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Amcinonide.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Amcinonide.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Amcinonide.Experimental
Bismuth SubcitrateThe bioavailability of Amcinonide can be decreased when combined with Bismuth Subcitrate.Approved
Bismuth subnitrateThe bioavailability of Amcinonide can be decreased when combined with Bismuth subnitrate.Experimental
BoceprevirThe serum concentration of Amcinonide can be increased when it is combined with Boceprevir.Approved, Withdrawn
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Amcinonide.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Amcinonide.Investigational
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Amcinonide.Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Amcinonide.Experimental
BumetanideAmcinonide may increase the hypokalemic activities of Bumetanide.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Amcinonide.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Amcinonide can be decreased when combined with Calcium Carbonate.Approved
Calcium silicateThe bioavailability of Amcinonide can be decreased when combined with Calcium silicate.Experimental
Capromab pendetideAmcinonide may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CarbamazepineThe serum concentration of Amcinonide can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Amcinonide.Experimental, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Amcinonide.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Amcinonide.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Amcinonide.Approved, Investigational
CeritinibAmcinonide may increase the hyperglycemic activities of Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Amcinonide.Approved, Vet Approved
ChlorothiazideAmcinonide may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Amcinonide can be increased when it is combined with Chlorotrianisene.Investigational, Withdrawn
ChlorthalidoneAmcinonide may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Amcinonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Amcinonide.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Cinoxacin.Approved, Investigational, Withdrawn
ClarithromycinThe serum concentration of Amcinonide can be increased when it is combined with Clarithromycin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Amcinonide.Approved
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Amcinonide is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
CobicistatThe serum concentration of Amcinonide can be increased when it is combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Amcinonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Amcinonide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Conjugated estrogensThe serum concentration of Amcinonide can be increased when it is combined with Conjugated estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Amcinonide.Approved
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Amcinonide is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CoumaphosThe risk or severity of adverse effects can be increased when Amcinonide is combined with Coumaphos.Vet Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Amcinonide.Investigational
CyclopenthiazideAmcinonide may increase the hypokalemic activities of Cyclopenthiazide.Experimental
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Amcinonide.Investigational
DaidzeinThe serum concentration of Amcinonide can be increased when it is combined with Daidzein.Experimental
DarunavirThe serum concentration of Amcinonide can be increased when it is combined with Darunavir.Approved
DecamethoniumThe risk or severity of adverse effects can be increased when Amcinonide is combined with Decamethonium.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Amcinonide is combined with Deferasirox.Approved, Investigational
DemecariumThe risk or severity of adverse effects can be increased when Amcinonide is combined with Demecarium.Approved
dersalazineThe risk or severity of adverse effects can be increased when dersalazine is combined with Amcinonide.Investigational
DichlorvosThe risk or severity of adverse effects can be increased when Amcinonide is combined with Dichlorvos.Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Amcinonide.Approved, Vet Approved
DienestrolThe serum concentration of Amcinonide can be increased when it is combined with Dienestrol.Approved, Investigational
DiethylstilbestrolThe serum concentration of Amcinonide can be increased when it is combined with Diethylstilbestrol.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Amcinonide.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Amcinonide.Approved
DihydrotestosteroneAmcinonide may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DistigmineThe risk or severity of adverse effects can be increased when Amcinonide is combined with Distigmine.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Amcinonide is combined with Donepezil.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Amcinonide.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Amcinonide.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Amcinonide.Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Amcinonide is combined with Echothiophate.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Amcinonide is combined with Edrophonium.Approved
EnoxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of Amcinonide can be decreased when it is combined with Enzalutamide.Approved
EpimestrolThe serum concentration of Amcinonide can be increased when it is combined with Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Amcinonide.Approved
EquolThe serum concentration of Amcinonide can be increased when it is combined with Equol.Investigational
EstradiolThe serum concentration of Amcinonide can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Amcinonide can be increased when it is combined with Estriol.Approved, Investigational, Vet Approved
EstroneThe serum concentration of Amcinonide can be increased when it is combined with Estrone.Approved
Etacrynic acidAmcinonide may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Amcinonide.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Amcinonide.Experimental
Ethinyl EstradiolThe serum concentration of Amcinonide can be increased when it is combined with Ethinyl Estradiol.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Amcinonide.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Amcinonide.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Amcinonide.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Amcinonide.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Amcinonide.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Amcinonide.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Amcinonide.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Amcinonide.Approved
FenthionThe risk or severity of adverse effects can be increased when Amcinonide is combined with Fenthion.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Amcinonide.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Amcinonide.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Amcinonide.Experimental
FleroxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Amcinonide.Approved, Withdrawn
FlumequineThe risk or severity of adverse effects can be increased when Amcinonide is combined with Flumequine.Withdrawn
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Amcinonide.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Amcinonide.Experimental
FluoxymesteroneAmcinonide may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Amcinonide.Approved, Investigational
FosaprepitantThe serum concentration of Amcinonide can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Amcinonide can be decreased when it is combined with Fosphenytoin.Approved
FurosemideAmcinonide may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
G17DTThe risk or severity of adverse effects can be increased when Amcinonide is combined with G17DT.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Amcinonide is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Gatifloxacin.Approved, Investigational
GemifloxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Amcinonide can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Amcinonide is combined with GI-5005.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Amcinonide is combined with Ginkgo biloba.Approved, Investigational, Nutraceutical
GLPG-0492Amcinonide may increase the fluid retaining activities of GLPG-0492.Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Amcinonide.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Amcinonide.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Amcinonide.Experimental
HexestrolThe serum concentration of Amcinonide can be increased when it is combined with Hexestrol.Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Amcinonide.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Amcinonide is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Amcinonide.Approved, Investigational
HydrochlorothiazideAmcinonide may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideAmcinonide may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydrotalciteThe bioavailability of Amcinonide can be decreased when combined with Hydrotalcite.Experimental, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Amcinonide.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Amcinonide.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Amcinonide.Approved
IdelalisibThe serum concentration of Amcinonide can be increased when it is combined with Idelalisib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Amcinonide.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Amcinonide.Approved
IndapamideAmcinonide may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Amcinonide can be increased when it is combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Amcinonide.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Amcinonide.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Amcinonide.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Amcinonide is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Amcinonide is combined with INGN 225.Investigational
IpidacrineThe risk or severity of adverse effects can be increased when Amcinonide is combined with Ipidacrine.Experimental
IsoflurophateThe risk or severity of adverse effects can be increased when Amcinonide is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Amcinonide.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Amcinonide.Withdrawn
ItraconazoleThe serum concentration of Amcinonide can be increased when it is combined with Itraconazole.Approved, Investigational
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Amcinonide.Experimental
KetoconazoleThe serum concentration of Amcinonide can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Amcinonide.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Amcinonide.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Amcinonide.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Levofloxacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Amcinonide.Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Amcinonide.Experimental
LopinavirThe serum concentration of Amcinonide can be increased when it is combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Amcinonide.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Amcinonide.Approved, Investigational
LumacaftorThe serum concentration of Amcinonide can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Amcinonide.Approved, Investigational
MagaldrateThe bioavailability of Amcinonide can be decreased when combined with Magaldrate.Approved, Withdrawn
Magnesium HydroxideThe bioavailability of Amcinonide can be decreased when combined with Magnesium Hydroxide.Approved
Magnesium oxideThe bioavailability of Amcinonide can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Amcinonide can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Amcinonide.Approved
Magnesium silicateThe bioavailability of Amcinonide can be decreased when combined with Magnesium silicate.Approved, Experimental
Magnesium TrisilicateThe bioavailability of Amcinonide can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Amcinonide is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Amcinonide.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Amcinonide.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Amcinonide.Approved
MefloquineThe risk or severity of adverse effects can be increased when Amcinonide is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Amcinonide.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Amcinonide is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Amcinonide.Approved
MesteroloneAmcinonide may increase the fluid retaining activities of Mesterolone.Experimental
MestranolThe serum concentration of Amcinonide can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Amcinonide.Investigational, Withdrawn
MethallenestrilThe serum concentration of Amcinonide can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Methanesulfonyl Fluoride.Investigational
MethyclothiazideAmcinonide may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Amcinonide is combined with Methyl salicylate.Approved, Vet Approved
MethyltestosteroneAmcinonide may increase the fluid retaining activities of Methyltestosterone.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Metoclopramide.Approved, Investigational
MetolazoneAmcinonide may increase the hypokalemic activities of Metolazone.Approved
MifepristoneThe therapeutic efficacy of Amcinonide can be decreased when used in combination with Mifepristone.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Amcinonide is combined with Minaprine.Approved
MitotaneThe serum concentration of Amcinonide can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Amcinonide.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Amcinonide.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Amcinonide.Experimental
MoxestrolThe serum concentration of Amcinonide can be increased when it is combined with Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Amcinonide.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Amcinonide.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Amcinonide.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Amcinonide.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Amcinonide.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Amcinonide is combined with Nalidixic Acid.Approved, Investigational
NandroloneAmcinonide may increase the fluid retaining activities of Nandrolone.Experimental, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Amcinonide.Approved, Vet Approved
NefazodoneThe serum concentration of Amcinonide can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Amcinonide can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Nemonoxacin.Investigational
NeostigmineThe risk or severity of adverse effects can be increased when Amcinonide is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Amcinonide.Approved
NevirapineThe serum concentration of Amcinonide can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Amcinonide is combined with Nicorandil.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Amcinonide.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Amcinonide.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Amcinonide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Amcinonide.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Norfloxacin.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Amcinonide.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Amcinonide.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Amcinonide.Vet Approved
OxandroloneAmcinonide may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Amcinonide.Approved
Oxolinic acidThe risk or severity of adverse effects can be increased when Amcinonide is combined with Oxolinic acid.Experimental
OxymetholoneAmcinonide may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Amcinonide.Approved, Withdrawn
ParaoxonThe risk or severity of adverse effects can be increased when Amcinonide is combined with Paraoxon.Experimental
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Amcinonide.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Amcinonide.Investigational
PazufloxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Pefloxacin.Approved
PentobarbitalThe serum concentration of Amcinonide can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PhenobarbitalThe serum concentration of Amcinonide can be decreased when it is combined with Phenobarbital.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Amcinonide.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Amcinonide.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Amcinonide.Approved, Investigational
PhenytoinThe serum concentration of Amcinonide can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe risk or severity of adverse effects can be increased when Amcinonide is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Amcinonide.Approved, Investigational
Pipemidic acidThe risk or severity of adverse effects can be increased when Amcinonide is combined with Pipemidic acid.Experimental
PiretanideAmcinonide may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Amcinonide.Approved, Investigational
Piromidic acidThe risk or severity of adverse effects can be increased when Amcinonide is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Amcinonide.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Amcinonide.Experimental
Polyestradiol phosphateThe serum concentration of Amcinonide can be increased when it is combined with Polyestradiol phosphate.Approved
PolythiazideAmcinonide may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe serum concentration of Amcinonide can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Amcinonide.Experimental, Investigational
PrimidoneThe serum concentration of Amcinonide can be decreased when it is combined with Primidone.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Amcinonide.Experimental
PromestrieneThe serum concentration of Amcinonide can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Amcinonide.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Amcinonide.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Amcinonide.Experimental
PrulifloxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Amcinonide.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Amcinonide is combined with Pyridostigmine.Approved
QuinestrolThe serum concentration of Amcinonide can be increased when it is combined with Quinestrol.Approved
QuinethazoneAmcinonide may increase the hypokalemic activities of Quinethazone.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Amcinonide is combined with Rabies virus inactivated antigen, A.Approved
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Amcinonide.Withdrawn
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Amcinonide.Approved, Experimental, Investigational
RifabutinThe serum concentration of Amcinonide can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Amcinonide can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Amcinonide can be decreased when it is combined with Rifapentine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Amcinonide is combined with Rindopepimut.Investigational
RitonavirThe serum concentration of Amcinonide can be increased when it is combined with Ritonavir.Approved, Investigational
RivastigmineThe risk or severity of adverse effects can be increased when Amcinonide is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Amcinonide.Investigational, Withdrawn
RosoxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Rosoxacin.Approved, Investigational
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Amcinonide is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Amcinonide is combined with Rubella virus vaccine.Approved
RufloxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Amcinonide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Amcinonide.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Amcinonide.Approved
SaquinavirThe serum concentration of Amcinonide can be increased when it is combined with Saquinavir.Approved, Investigational
SecoisolariciresinolThe serum concentration of Amcinonide can be increased when it is combined with Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Amcinonide.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Amcinonide.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Amcinonide.Investigational
SitafloxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Sitafloxacin.Experimental, Investigational
SparfloxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Sparfloxacin.Approved, Investigational
SRP 299The risk or severity of adverse effects can be increased when Amcinonide is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Amcinonide.Investigational
St. John's WortThe serum concentration of Amcinonide can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StanozololAmcinonide may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Amcinonide can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Amcinonide.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Amcinonide.Approved
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Amcinonide.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Amcinonide.Experimental
Synthetic Conjugated Estrogens, AThe serum concentration of Amcinonide can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Amcinonide can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Amcinonide is combined with Tacrine.Investigational, Withdrawn
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Amcinonide.Investigational
TecemotideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Tecemotide.Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Amcinonide.Approved, Withdrawn
TelithromycinThe serum concentration of Amcinonide can be increased when it is combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Temafloxacin.Withdrawn
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Amcinonide.Experimental
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Amcinonide.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Amcinonide.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Amcinonide.Approved
TestosteroneAmcinonide may increase the fluid retaining activities of Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Amcinonide is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Amcinonide.Approved
TiboloneThe serum concentration of Amcinonide can be increased when it is combined with Tibolone.Approved, Investigational
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Amcinonide.Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Amcinonide.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Amcinonide.Approved
TorasemideAmcinonide may increase the hypokalemic activities of Torasemide.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Amcinonide.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Amcinonide.Experimental
TrichlorfonThe risk or severity of adverse effects can be increased when Amcinonide is combined with Trichlorfon.Vet Approved
TrichlormethiazideAmcinonide may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Amcinonide.Investigational
TrovafloxacinThe risk or severity of adverse effects can be increased when Amcinonide is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Amcinonide is combined with Tubocurarine.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Amcinonide.Investigational, Withdrawn
VoriconazoleThe serum concentration of Amcinonide can be increased when it is combined with Voriconazole.Approved, Investigational
WarfarinAmcinonide may increase the anticoagulant activities of Warfarin.Approved
Yellow fever vaccineThe risk or severity of adverse effects can be increased when Amcinonide is combined with Yellow fever vaccine.Approved
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Amcinonide.Approved, Investigational
ZeranolThe serum concentration of Amcinonide can be increased when it is combined with Zeranol.Vet Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Amcinonide.Approved, Investigational, Withdrawn
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Amcinonide.Withdrawn
Zoster vaccineThe risk or severity of adverse effects can be increased when Amcinonide is combined with Zoster vaccine.Approved
Food Interactions
Not Available

References

Synthesis Reference

Schultz, W., Sieger, G.M. and Krieger, C.: British Patent 1,442,925; July 14,1976; assigned to American Cyanamid Company.

General References
Not Available
External Links
Human Metabolome Database
HMDB14433
KEGG Drug
D01387
PubChem Compound
443958
PubChem Substance
46506705
ChemSpider
392009
ChEBI
31199
ChEMBL
CHEMBL1200732
Therapeutic Targets Database
DAP001044
PharmGKB
PA164746074
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Amcinonide
ATC Codes
D07AC11 — Amcinonide
AHFS Codes
  • 84:06.00 — Anti-inflammatory Agents
FDA label
Download (143 KB)
MSDS
Download (48.1 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Altana inc
  • Taro pharmaceutical industries ltd
  • Astellas pharma us inc
Packagers
Dosage forms
FormRouteStrength
CreamTopical1 mg/g
LotionTopical1 mg/g
OintmentTopical1 mg/g
CreamTopical0.1 %
OintmentTopical0.1 %
CreamTopical.1 %
LotionTopical.1 %
OintmentTopical.1 %
LotionTopical0.1 %
Prices
Unit descriptionCostUnit
Amcinonide 0.1% Cream 60 gm Tube84.29USD tube
Amcinonide 0.1% Ointment 60 gm Tube84.29USD tube
Amcinonide 0.1% Cream 30 gm Tube28.71USD tube
Amcinonide 0.1% Cream 15 gm Tube20.99USD tube
Amcinonide 0.1% cream1.68USD g
Cyclocort 0.1 % Cream0.62USD g
Cyclocort 0.1 % Ointment0.62USD g
Cyclocort 0.1 % Lotion0.52USD g
Ratio-Amcinonide 0.1 % Ointment0.33USD g
Ratio-Amcinonide 0.1 % Cream0.29USD g
Taro-Amcinonide 0.1 % Cream0.29USD g
Ratio-Amcinonide 0.1 % Lotion0.27USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP2.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00774 mg/mLALOGPS
logP3.16ALOGPS
logP3.2ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)13.63ChemAxon
pKa (Strongest Basic)-3.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area99.13 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity127.88 m3·mol-1ChemAxon
Polarizability52.23 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9643
Blood Brain Barrier+0.9897
Caco-2 permeable-0.5844
P-glycoprotein substrateSubstrate0.7713
P-glycoprotein inhibitor IInhibitor0.7198
P-glycoprotein inhibitor IIInhibitor0.5596
Renal organic cation transporterNon-inhibitor0.7608
CYP450 2C9 substrateNon-substrate0.8615
CYP450 2D6 substrateNon-substrate0.9016
CYP450 3A4 substrateSubstrate0.7307
CYP450 1A2 substrateNon-inhibitor0.8688
CYP450 2C9 inhibitorNon-inhibitor0.8732
CYP450 2D6 inhibitorNon-inhibitor0.8982
CYP450 2C19 inhibitorNon-inhibitor0.9188
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8999
Ames testNon AMES toxic0.8886
CarcinogenicityNon-carcinogens0.941
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4315 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9488
hERG inhibition (predictor II)Non-inhibitor0.5298
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-024i-3891000000-ef24dafd204a6e82ead7

Taxonomy

Description
This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Pregnane steroids
Direct Parent
Gluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
20-oxosteroids / 11-beta-hydroxysteroids / 3-oxo delta-1,4-steroids / Halogenated steroids / Delta-1,4-steroids / Alpha-acyloxy ketones / Ketals / 1,3-dioxolanes / Fluorohydrins / Cyclic ketones
show 9 more
Substituents
Progestogin-skeleton / 20-oxosteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / 9-halo-steroid / Halo-steroid / Hydroxysteroid / Oxosteroid / 11-beta-hydroxysteroid / 11-hydroxysteroid
show 27 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
acetate ester, spiroketal, 11beta-hydroxy steroid, 20-oxo steroid, fluorinated steroid, 3-oxo-Delta(1),Delta(4)-steroid, corticosteroid (CHEBI:31199)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Grossman R, Yehuda R, Golier J, McEwen B, Harvey P, Maria NS: Cognitive effects of intravenous hydrocortisone in subjects with PTSD and healthy control subjects. Ann N Y Acad Sci. 2006 Jul;1071:410-21. [PubMed:16891588]
  4. Rautanen A, Eriksson JG, Kere J, Andersson S, Osmond C, Tienari P, Sairanen H, Barker DJ, Phillips DI, Forsen T, Kajantie E: Associations of body size at birth with late-life cortisol concentrations and glucose tolerance are modified by haplotypes of the glucocorticoid receptor gene. J Clin Endocrinol Metab. 2006 Nov;91(11):4544-51. Epub 2006 Aug 8. [PubMed:16895953]
  5. Hammer F, Stewart PM: Cortisol metabolism in hypertension. Best Pract Res Clin Endocrinol Metab. 2006 Sep;20(3):337-53. [PubMed:16980198]
  6. Shaw JR, Gabor K, Hand E, Lankowski A, Durant L, Thibodeau R, Stanton CR, Barnaby R, Coutermarsh B, Karlson KH, Sato JD, Hamilton JW, Stanton BA: Role of glucocorticoid receptor in acclimation of killifish (Fundulus heteroclitus) to seawater and effects of arsenic. Am J Physiol Regul Integr Comp Physiol. 2007 Feb;292(2):R1052-60. Epub 2006 Oct 12. [PubMed:17038445]
  7. Sher L: Combined dexamethasone suppression-corticotropin-releasing hormone stimulation test in studies of depression, alcoholism, and suicidal behavior. ScientificWorldJournal. 2006 Oct 31;6:1398-404. [PubMed:17086345]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Structural molecule activity
Specific Function
Plays important roles in the innate immune response as effector of glucocorticoid-mediated responses and regulator of the inflammatory process. Has anti-inflammatory activity (PubMed:8425544). Play...
Gene Name
ANXA1
Uniprot ID
P04083
Uniprot Name
Annexin A1
Molecular Weight
38713.855 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Serres M, Comera C, Schmitt D: Annexin 1 regulation in human epidermal cells. Cell Mol Biol (Noisy-le-grand). 1994 Jul;40(5):701-6. [PubMed:7981624]

Drug created on June 13, 2005 07:24 / Updated on November 13, 2017 21:49